Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
LENSAR ( (LNSR) ) just unveiled an update.
On March 23, 2025, LENSAR, Inc. entered into a merger agreement with Alcon Research, LLC, where LENSAR will become a wholly owned subsidiary of Alcon. The agreement involves Alcon acquiring all outstanding shares of LENSAR for $14.00 per share in cash, with an additional contingent value right of $2.75 per share based on achieving certain milestones. This acquisition aims to strengthen Alcon’s cataract equipment portfolio and expand the use of LENSAR’s advanced femtosecond laser technology globally. The transaction, valued at up to $430 million, is expected to close in mid-to-late 2025, pending regulatory and stockholder approvals.
More about LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism. The company has developed the ALLY Robotic Cataract Laser System, which integrates AI into its imaging and software to enhance cataract surgery procedures.
YTD Price Performance: 70.54%
Average Trading Volume: 112,621
Technical Sentiment Signal: Sell
Current Market Cap: $174.7M
See more insights into LNSR stock on TipRanks’ Stock Analysis page.